$ 69 / 10mg
999 in stock (can be backordered)
Ipamorelin is a synthetic pentapeptide GHS-R1a agonist recognized as one of the most selective growth-hormone secretagogues available for research. Unlike other GHRPs, Ipamorelin peptide promotes pulsatile GH release without significantly affecting cortisol, ACTH, or prolactin levels — making it the preferred tool for researchers who need clean GH-axis data without confounding hormonal variables.
Ipamorelin peptide selectively activates ghrelin receptors (GHS-R1a) on anterior pituitary somatotrophs, triggering calcium influx and GH granule exocytosis. Its selectivity stems from minimal cross-reactivity with other pituitary receptor subtypes. In dose-escalation studies, Ipamorelin maintains a linear dose-response for GH release up to a saturation point, without the cortisol and appetite spikes seen with less selective secretagogues like GHRP-6.
The CJC-1295 + Ipamorelin combination is the most popular pairing, adding GHRH-receptor activation for amplified GH release. Hexarelin offers the highest-potency alternative, while Sermorelin provides a GHRH-only approach for pathway-comparison studies.
Each vial contains Ipamorelin peptide manufactured in the USA under ISO-certified conditions. Verified to ≥99% purity by HPLC analysis, with endotoxin screening below 0.1 EU/mg. Certificate of Analysis (COA) available upon request. For laboratory research use only.
Lyophilized Ipamorelin peptide should be stored at -20°C upon receipt to preserve its GH-secretagogue activity and chemical stability. Keep vials sealed and protected from light, heat, and moisture during storage. Reconstitute with bacteriostatic water (0.9% benzyl alcohol) when ready for use, allowing the lyophilized powder to dissolve gently without vigorous shaking. Once reconstituted, store the peptide solution at 2–8°C and use within 28 days for reliable experimental results. Avoid repeated freeze-thaw cycles, as this can degrade the pentapeptide structure and reduce GHS-R1a binding affinity. Handle under standard aseptic laboratory conditions. For research use only.
Ipamorelin was first developed in the late 1990s by Novo Nordisk as part of a program to identify highly selective growth hormone secretagogues. It was designed as a pentapeptide agonist of the ghrelin receptor (GHS-R1a) with minimal off-target endocrine effects, distinguishing it from earlier secretagogues such as GHRP-6 and GHRP-2. Initial characterization studies published in the European Journal of Endocrinology and Endocrinology demonstrated its unique selectivity profile — robust GH release without elevation of cortisol, ACTH, or prolactin. Since its development, Ipamorelin has been referenced in over 150 peer-reviewed publications across growth-hormone physiology, body-composition research, and circadian GH-pulse studies. Key contributions have come from Novo Nordisk’s internal research division, the University of Copenhagen, and various academic endocrinology departments. Ipamorelin remains the gold-standard selective secretagogue in GH-axis research. All references pertain to laboratory and preclinical research contexts only.
Ipamorelin activates GHS-R1a receptors on pituitary somatotrophs with minimal cross-reactivity at other receptor subtypes, producing pulsatile GH release without elevating cortisol, ACTH, or prolactin. This clean pharmacological profile distinguishes it from less selective secretagogues like GHRP-6 or GHRP-2 that trigger broader hormonal responses. This product is supplied for laboratory research use only.
Ipamorelin is manufactured in the USA under ISO-certified conditions and verified to ≥99% purity by HPLC analysis, with endotoxin screening confirmed below 0.1 EU/mg. A Certificate of Analysis (COA) with complete analytical data is available upon request for research documentation and compliance records.
CJC-1295 activates GHRH receptors while Ipamorelin activates GHS-R1a (ghrelin) receptors — two complementary pathways that synergistically amplify GH release beyond what either compound achieves alone. This dual-pathway approach allows researchers to study the interaction between GHRH and ghrelin signaling in GH secretion models. Both products are intended for research use only.
